GlassScriptPhysician profile
Jerold Steven Napier
NPI 1376526707
$2,792.39
in general payments reported to CMS, 2019-2025
32 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $568 · 2021: $579 · 2022: $488 · 2023: $142 · 2024: $325 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602 · Education: $18.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.25 |
| Education | $18.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $256.06 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $243.36 | 2020-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $231.62 | 2019-2023 | Evusheld |
| Opko Pharmaceuticals, LLC | $196.76 | 2019-2023 | Rayaldee |
| Genentech USA, INC. | $160.68 | 2019 | |
| Amgen INC. | $158.84 | 2020-2025 | Otezla, Repatha, Tavneos |
| Pfizer INC. | $144.81 | 2019-2021 | |
| Akebia Therapeutics INC | $128.90 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $118.31 | 2019-2024 | Ultomiris |
| Horizon Therapeutics Plc | $111.01 | 2020-2022 | |
| Novo Nordisk INC | $110.10 | 2019-2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $96.05 | 2021-2024 | |
| Ucb, INC. | $85.20 | 2020-2025 | Cimzia, Bimzelx |
| Otsuka America Pharmaceutical, INC. | $84.98 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $83.48 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $76.60 | 2024 | Nxstage System One |
| Medtronic, INC. | $70.97 | 2021-2025 | Symplicity G3 |
| Janssen Biotech, INC. | $57.56 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.39 | 2021-2024 | Jardiance, Synjardy |
| Travere Therapeutics, INC. | $37.74 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $36.94 | 2019 | |
| Genzyme Corporation | $35.07 | 2019-2021 | |
| Glaxosmithkline, LLC. | $34.88 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $32.27 | 2020-2024 | Crysvita |
| Bard Peripheral Vascular, INC. | $29.25 | 2020 | |
| Lilly USA, LLC | $21.10 | 2024 | Zepbound, Mounjaro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.97 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.45 | 2024 | Oxlumo |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2020 | |
| Celgene Corporation | $14.89 | 2019 | |
| Shire North American Group INC | $14.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerold Napier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.